3 results match your criteria: "Hospital Universitari Mútua Terrassa (HUMT)[Affiliation]"
Negative hyperselection beyond RAS: is a key tool for choosing the optimal maintenance treatment in metastatic colorectal cancer?
J Gastrointest Oncol
October 2024
Medical Oncology Department, Hospital Universitari Mútua Terrassa (HUMT), Terrassa, Spain.
Cognitive Profile and Cardiovascular Risk Factors in Older Adults with Mild Cognitive Impairment.
Int J Environ Res Public Health
April 2024
RE-FiT Barcelona Research Group, Vall d'Hebron Institute of Research & Parc Sanitari Pere Virgili (VHIR-PSPV), 08023 Barcelona, Spain.
The prevalence of cardiovascular risk factors (CVRFs) in the older adults population and their specific impact on their cognitive profiles still requires further research. For this purpose, a cross-sectional study was carried out to describe the presence of CVRFs and their association with cognitive performance in a sample of older adults (65-85 years old) with Mild Cognitive Impairment (MCI). Participants ( = 185) were divided into three groups concerning their cardiovascular risk level determined by the presence of different CVRFs, including Type 2 Diabetes (T2D), dyslipidemia, hypertension, and obesity.
View Article and Find Full Text PDFUltrasound Guided High Intensity Focused Ultrasound for malignant tumors: The Spanish experience of survival advantage in stage III and IV pancreatic cancer.
Ultrason Sonochem
November 2015
Medical Direction Departments, Hospital Universitari Mutua Terrassa (HUMT), Pl. Dr. Robert, 5, 08221 Terrassa, Barcelona, Spain.
Unlabelled: We described the experience of the HIFU Onco Unit of Hospital University Mutua Terrassa (Barcelona, Spain) treating malignant tumors, focusing on results of unresectable pancreatic tumors treated with Ultrasound Guided High Intensity Focused Ultrasound (USgHIFU) hyperthermia ablation in combination with adjuvant chemotherapy.
Materials And Methods: From February 2008 to December 2013, we treated 140 malignant cases. Of those, 48 cases of unresectable pancreatic tumors were treated from March 2010 to December 2013, and the first 43 were included in the analysis.